The invention relates to non direct A Nagy Lea Nagy Ray release active substances caused by new preparations.Inventors have shown that anagray includes granular pharmaceutical compositions in which at least 90% of the particles are mu_kappa p_epsilon Therefore, 10 micron m combined with lactose reduces the release characteristics when supplied to the patient.Optionally, the composition may also contain polyvinyl ketone, crosslinked polyvinylpyrrolidone, microcrystalline cellulose and/or magnesium stearate.
展开▼
机译：本发明涉及由新制剂引起的非直接的A Nagy Lea Nagy Ray释放活性物质。发明人已经表明，anagray包括粒状药物组合物，其中至少90％的颗粒是mu_kappa p_epsilon，因此，与乳糖结合的10微米可降低当提供给患者时，其释放特性。任选地，组合物还可包含聚乙烯酮，交联的聚乙烯吡咯烷酮，微晶纤维素和/或硬脂酸镁。
展开▼
